Novartis hit after data probe

Novartis shares have fallen after US regulators said a unit that developed a costly breakthrough gene therapy knew about potential manipulation of animal testing data but failed to disclose it before the treatment was approved.

Novartis hit after data probe

By Michelle Fay Cortez and Anna Edney

Novartis shares have fallen after US regulators said a unit that developed a costly breakthrough gene therapy knew about potential manipulation of animal testing data but failed to disclose it before the treatment was approved.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited